Compare Amgen, Inc. (AMGN) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Harley-Davidson Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Harley-Davidson Inc trades at $25.14 (market cap $2.65B). The key difference: Amgen, Inc. is far larger — about 74× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| AMGN | HOG | |
|---|---|---|
Market Cap | $196.12B | $2.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $31.03 |
52-Week Low | $271.18 | $17.19 |
Enterprise Value | $241.41B | $3.04B |
Dividend Yield | 2.77% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Harley-Davidson (HOG) trades at $25.14, up 1.17% today, with a neutral technical outlook and mixed earnings history. The company reported Q1 2026 EPS of $0.22, missing estimates, but Q2 2026 results are due July 23, 2026. Recent news highlights production shifts back to the U.S. and cost-cutting initiatives. Valuation ratios appear attractive with a P/E of 13.03 and P/B of 0.86, though revenue has declined from $5.8B in 2023 to $4.5B in 2025.
The stock faces headwinds from declining revenue and margin pressure, but cost reductions and strategic shifts under new CEO Artie Starrs offer turnaround potential. Analyst consensus is cautious with a $23.20 price target below current levels. Key risks include competitive pressures and execution challenges. The upcoming Q2 earnings will be critical for confirming demand recovery and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
